Receptors, signalling and cardiac pharmacology

 
Finn Olav Levy<br>Group leader
Finn Olav Levy
Group leader

Patients with heart failure (HF) have high morbidity and poor prognosis. To develop new treatments, better understanding of the mechanisms of myocardial function in normal and failing hearts and of the development of HF is needed. Several receptors (e.g. beta-adrenoceptors (βAR), 5-HT4 serotonin receptors) increase cardiac contractile function through the cAMP signaling system. This response is energetically expensive and therefore detrimental in the long term and should be avoided in HF. Blocking βARs is therefore important in HF treatment. While increased understanding can provide novel ways to reduce these signaling pathways, understanding of other types of cardiac signaling may reveal novel methods to improve cardiac function in heart failure. Recent development in understanding of receptor function has important implications also for understanding and treatment of other diseases.

 
 

Research projects

 
  • Importance of serotonin receptors and natriuretic peptide receptors in heart failure
  • Signaling mechanisms regulating contractile function in normal and failing hearts
  • Compartmentation of receptor-mediated cAMP and cGMP signaling in normal and failing hear Implications for treatment of heart failure
  • Importance of increased calcium efficiency in the failing heart
  • New understanding of receptor function: Functional selectivity and receptor-G protein interaction
 
 
 
 
 
 

Contact information:
Group leader Professor Finn Olav Levy Department of Pharmacology University of Oslo and Oslo University Hospital PO Box 1057 Blindern NO-0316 Oslo, Norway, Tel: +47 22840237 E-mail: f.o.levy@medisin.uio.no